Needham & Company
-
CTI BioPharma (CTIC) PT Lowered to $5 at Needham & Company on PDUFA Delay
-
CTI BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, Apr. 14
-
CTI BioPharma (CTIC) PT Raised Nearly Doubled to $6 at Needham & Company
-
CTI BioPharma to Present at the Needham Healthcare Conference on Wednesday, Apr. 15
-
CTI BioPharma to Present at the 18th Annual Needham Healthcare Conference on Wednesday, Apr. 10
-
CTI BioPharma (CTIC) PT Lowered to $4 at Needham & Company
-
CTI BioPharma (CTIC) PT Lowered to $7 at Needham & Company
-
Needham & Company Starts CTI BioPharma (CTIC) at Buy
-
CTI BioPharma to Present at Upcoming Investor Conferences
-
CTI BioPharma Announces Closing Of Underwritten Public Offering Of Common Stock
-
CTI BioPharma (CTIC) Prices 20M Shares at $3
-
CTI BioPharma Prices Underwritten Public Offering of $60 Million of Common Stock
-
CTI BioPharma (CTIC) Launches Follow-On Offering of Common Stock
-
CTI BioPharma Announces Launch of Follow-On Offering
-
Notable 52-Week Highs and Lows 3/13: (AMRN) (NXPI) (BMRN) High; (CTIC) (GALE) (HERO) Low
-
Notable Analyst Rating Changes 10/15: (LOW) (SNDK) (CLWR) Upgraded; (WFC) (TC) (CYS) Downgraded
-
Morning Movers 2/9: ACLI, CTIC, HAR, ADCT, COIN Higher; TRGL, CONN, TRID, TMRK Lower

